06 Sep 2019

A GROUPON DEAL: DEALS FOR MEDICAL TREATMENT? WELCOME TO TODAY’S U.S. HEALTHCARE

By Lauren Weber KHS illustration by Lynne Shallcross     Emory University medical fellow Dr. Nicole Herbst was shocked when she saw three patients who came in with abnormal results from chest CT scans they had bought on Groupon. Yes, Groupon — the online coupon mecca that also sells discounted fitness classes and foosball

0
03 Sep 2019

DOCTOR FIRED: CATHOLIC HOSPITAL SETS OFF NATIONAL CHALLENGE TO AID-IN-DYING LAWS

By JoNel Aleccia KHN photos by Heidi de Marco   Dr. Barbara Morris, a geriatrician with Centura Health, was recently fired for wanting to help her patient with Colorado’s End of Life Options Act. A Catholic-run health system in Denver, Colorado, has fired a veteran doctor who went to court to

0
26 Aug 2019

COMING OUT ABOUT MENTAL HEALTH ON SOCIAL MEDIA

By Tarena Lofton Susanna Harris was sitting in her lab class for her graduate program at the University of North Carolina at Chapel Hill when she received an email that told her she had failed what she describes as “the most important exam in grad school,” the doctoral qualifying exam.

0
26 Jun 2019

VIVA AND THE VEINS 2019: Dr. Suresh Vedantham to receive VEIN Award; abstracts now being accepted

Suresh Vedantham, MD, past president of the Society of Interventional Radiology, will receive the 2019 Venous Educator, Innovator, and National Statesman Award (VEIN AWARD) during VIVA and The VEINS2019 conference Nov. 4-7 at the Wynn Las Vegas. Dr. Vedantham is a professor of Radiology & Surgery at the Mallinckrodt Institute of Radiology at the

0
26 Jun 2019

 ANGIODYNAMICS SELLS NAMIC fluid management portfolio

AngioDynamics Inc., a provider of innovative, minimally invasive medical devices for oncology, vascular access and peripheral vascular disease, has agreed to sell its NAMIC fluid management portfolio to Medline Industries Inc. for $167.5 million, subject to customary closing conditions including antitrust review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The

0
26 Jun 2019

F:LIP/FOCUS: LIVE, INTERACTIVE, PRACTICAL:AVLS OPENS REGISTRATION FOR 33RD ANNUAL CONGRESS NOV. 7-10 IN PHOENIX

By Larry Storer Online registration for the American Vein and Lymphatic Society’s 33rd Annual Congress, Nov. 7-10 at the JW Marriott Desert Ridge Resort and Spa in Phoenix, opened May 6 at avlscongress.org. “Early in 2018, Elsevier reported that medical knowledge was doubling every few months, posing serious challenges to

0
26 Jun 2019

CHARING CROSS 2019: MEDTRONIC EXPANDS ON KEY AORTIC SOLUTIONS FOR CHALLENGING ANATOMIES

  Medtronic plc released new data on endovascular repair of abdominal aortic aneurysm (AAA) patients with the Endurant II/IIs stent graft system in combination with Heli-FX EndoAnchor implants and for the Valiant Navion thoracic stent graft system for thoracic endovascular repair (TEVAR). The data, which was presented at the Charing Cross

0
26 Jun 2019

46th VEITHSYMPOSIUM SET FOR NOV. 19-23

  VEITHsymposium is planning the 46th Annual Symposium for Nov. 19-23 at the New York Hilton Midtown. The five-day event features rapid-fire presentations from world renowned vascular specialists with emphasis on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques Abstracts are being accepted at

0
26 Jun 2019

VEIN SPECIALISTS ADDS NEW NURSE

    Adelene Tolisano, MSN, APRN-C, has joined Vein Specialists in Fort Myers, Florida. Nurse Tolisano assists Joseph Magnant, MD, and his team in performing new patient, pre-operative and post-operative evaluations. She graduated from Florida Southwestern State College where she earned her bachelors in Nursing. She then went on to

0
26 Jun 2019

ABBVIE ACQUIRING ALLERGAN AS HEDGE AGAINST EXPIRATION OF HUMIRA PATENT

As a hedge against the 2023 expiration of its U.S. patents that protect its blockbuster drug, Humira, AbbVie Inc. will acquire Dublin, Ireland-based Allergan for $63 billion in cash and stock.     Humira sales account for more than 60 percent of AbbVie’s revenue, but biosimilar drugs approved in Europe

0